Uber’s move to ditch the ersatz earnings measure now that it’s a $193 bln giant might seem a win for orthodox accounting ...

Some 40% of drugs launched in the US have yet to make it to Europe. The White House's campaign to level prices globally may see pharmaceutical groups cut back further. This may lead to a political ...

Groww secured a punchy $7 bln valuation for its debut. Sovereign funds piled in. Investors are betting the country's largest stockbroker can rapidly diversify its business or, more likely, that the ...

The US president’s campaign for fossil fuels and against the energy transition will cause trouble for future generations. Yet ...

The US drug giant beat Novo Nordisk in the $10 bln battle for biotech Metsera with the help of the Federal Trade Commission. Though the regulator’s intervention was warranted, its speed was surprising ...

The $54 bln drinks group is betting on Tesco veteran Dave Lewis to revive its fortunes. The turnaround specialist faces a tough outlook of stagnant sales and changing consumer trends. His retail ...

Britain's top property portal tumbled up to 28% after it raised spending on artificial intelligence. While hurting margins, ...

Welcome back! For the first time in a while, the U.S. stock market is falling. The S&P 500 Index has shed 4% from its peak on October 29, while the tech-heavy Nasdaq Composite Index is down 6%. Is ...

The $51 bln Aussie investment bank's squeezed out an anaemic first-half return on equity below 10%. That isn't expected to ...

The world’s top wind turbine maker’s stock jumped 14% on onshore project profitability. Despite US hostility, AI-driven power ...

Associated British Foods may break off its fashion business from its unit that makes tea bags and sugar. A split makes sense, ...

Brian Roberts’s US giant is in talks to buy the UK broadcaster’s TV unit for $2 bln. The price is right for the seller, and ...